Drug Approval | October 18, 2023
Glenmark's current portfolio consists of 188 products authorized for distribution in the US
Multi-million dollar investment augments in-vitro biology capabilities in primary and secondary screening
Lupin enters into BTA with Lupin Manufacturing Solutions
Punit has more than 20 years of experience in the generics and branded pharmaceutical marketplace
Lupin is exclusive first-to-file and may be eligible to receive a 180-day exclusivity period at product launch
Astria will assume full cost and responsibility for the global development and commercialization of the licensed therapeutic program for all indications
India confronts alarming rates of eye disorders, propelling the urgency of eyecare awareness
Eni will guarantee Dompé researchers access to its laboratories, support from the company's specialized staff, and use of its HPC5 supercomputer
Alignment of carbon-fiber can be controlled during the 3D printing process
Subscribe To Our Newsletter & Stay Updated
